Paclitaxel

erb-b2 receptor tyrosine kinase 2 ; Homo sapiens







381 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
351 11694787 Interaction between Herceptin and taxanes. 2001 1
352 11706391 Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. 2001 Oct 11
353 11759824 Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. 2001 Sep 1
354 11770175 [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer]. 2001 Nov 18 2
355 11787463 Trastuzumab: new preparation. May help some patients with breast cancer, but too many unknowns. 2001 Aug 1
356 11822753 Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. 2001 Nov 3
357 11989523 Trials of new combinations of Herceptin in metastatic breast cancer. 2001 Dec 2
358 10601557 Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. 2000 Jan 2
359 10623878 Role of HER2 gene overexpression in breast carcinoma. 2000 Feb 1
360 10656456 E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. 2000 Jan 21
361 10699953 Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. 2000 Mar 1 2
362 10749863 Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. 2000 Jun 9 2
363 10781891 Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. 2000 Apr 3 5
364 10873087 Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. 2000 Jun 1
365 10878580 Role of erbB2 in breast cancer chemosensitivity. 2000 Jul 1
366 10898354 Developments in chemotherapy of breast cancer. 2000 Jun 15 2
367 11236027 Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. 2000 Dec 1
368 11899388 Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. 2000 Apr 2
369 11970748 Rationale and use of epirubicin-based therapy in the adjuvant setting. 2000 Sep 2
370 12845342 Transcriptional targeting of the HER-2/neu oncogene. 2000 Dec 1
371 10211534 Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. 1999 Feb 1
372 10399623 c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. 1999 Apr-Jun 4
373 10534697 Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. 1999 Nov 2
374 9572489 Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. 1998 Apr 23 10
375 9661897 Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. 1998 Jul 1 6
376 9844631 Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. 1998 Nov 6
377 10388129 Paclitaxel in Breast Cancer. 1998 1
378 9285690 Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. 1997 Aug 18 10
379 9337349 Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) 1997 Oct 15 1
380 9374103 Future directions of paclitaxel-based therapy of breast cancer. 1997 Oct 5
381 8808711 Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. 1996 Sep 19 5